nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisoprolol—CYP2D6—Sorafenib—liver cancer	0.0845	0.38	CbGbCtD
Bisoprolol—CYP3A4—Sorafenib—liver cancer	0.0537	0.242	CbGbCtD
Bisoprolol—CYP2D6—Doxorubicin—liver cancer	0.0513	0.231	CbGbCtD
Bisoprolol—CYP3A4—Doxorubicin—liver cancer	0.0326	0.147	CbGbCtD
Bisoprolol—Cystitis—Epirubicin—liver cancer	0.00312	0.00403	CcSEcCtD
Bisoprolol—Infection—Sorafenib—liver cancer	0.0031	0.004	CcSEcCtD
Bisoprolol—Atrioventricular block—Doxorubicin—liver cancer	0.00308	0.00398	CcSEcCtD
Bisoprolol—Shock—Sorafenib—liver cancer	0.00307	0.00396	CcSEcCtD
Bisoprolol—Fluid retention—Epirubicin—liver cancer	0.00306	0.00396	CcSEcCtD
Bisoprolol—Nervous system disorder—Sorafenib—liver cancer	0.00306	0.00395	CcSEcCtD
Bisoprolol—Thrombocytopenia—Sorafenib—liver cancer	0.00305	0.00394	CcSEcCtD
Bisoprolol—Skin disorder—Sorafenib—liver cancer	0.00303	0.00391	CcSEcCtD
Bisoprolol—Neck pain—Doxorubicin—liver cancer	0.00302	0.0039	CcSEcCtD
Bisoprolol—Abnormal dreams—Doxorubicin—liver cancer	0.00295	0.00381	CcSEcCtD
Bisoprolol—Coma—Epirubicin—liver cancer	0.00295	0.00381	CcSEcCtD
Bisoprolol—Bladder pain—Epirubicin—liver cancer	0.00292	0.00377	CcSEcCtD
Bisoprolol—Cystitis noninfective—Doxorubicin—liver cancer	0.00292	0.00377	CcSEcCtD
Bisoprolol—Cystitis—Doxorubicin—liver cancer	0.00288	0.00373	CcSEcCtD
Bisoprolol—Pulmonary oedema—Epirubicin—liver cancer	0.00287	0.00371	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00284	0.00367	CcSEcCtD
Bisoprolol—Fluid retention—Doxorubicin—liver cancer	0.00284	0.00366	CcSEcCtD
Bisoprolol—Abnormal vision—Epirubicin—liver cancer	0.00282	0.00364	CcSEcCtD
Bisoprolol—Dyspnoea—Sorafenib—liver cancer	0.00278	0.00359	CcSEcCtD
Bisoprolol—Dyspepsia—Sorafenib—liver cancer	0.00274	0.00354	CcSEcCtD
Bisoprolol—Coma—Doxorubicin—liver cancer	0.00273	0.00353	CcSEcCtD
Bisoprolol—Bladder pain—Doxorubicin—liver cancer	0.0027	0.00349	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Sorafenib—liver cancer	0.00269	0.00347	CcSEcCtD
Bisoprolol—Fatigue—Sorafenib—liver cancer	0.00269	0.00347	CcSEcCtD
Bisoprolol—Photosensitivity—Epirubicin—liver cancer	0.00267	0.00345	CcSEcCtD
Bisoprolol—Constipation—Sorafenib—liver cancer	0.00266	0.00344	CcSEcCtD
Bisoprolol—Pain—Sorafenib—liver cancer	0.00266	0.00344	CcSEcCtD
Bisoprolol—Pulmonary oedema—Doxorubicin—liver cancer	0.00266	0.00343	CcSEcCtD
Bisoprolol—Vascular purpura—Epirubicin—liver cancer	0.00262	0.00338	CcSEcCtD
Bisoprolol—Eczema—Epirubicin—liver cancer	0.00261	0.00337	CcSEcCtD
Bisoprolol—Abnormal vision—Doxorubicin—liver cancer	0.0026	0.00336	CcSEcCtD
Bisoprolol—Eye pain—Epirubicin—liver cancer	0.0026	0.00335	CcSEcCtD
Bisoprolol—Cardiac failure congestive—Epirubicin—liver cancer	0.00258	0.00334	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Sorafenib—liver cancer	0.00255	0.00329	CcSEcCtD
Bisoprolol—Hot flush—Epirubicin—liver cancer	0.0025	0.00324	CcSEcCtD
Bisoprolol—Dermatitis exfoliative—Epirubicin—liver cancer	0.00248	0.00321	CcSEcCtD
Bisoprolol—Menopausal symptoms—Epirubicin—liver cancer	0.00248	0.00321	CcSEcCtD
Bisoprolol—Urticaria—Sorafenib—liver cancer	0.00248	0.0032	CcSEcCtD
Bisoprolol—Photosensitivity—Doxorubicin—liver cancer	0.00247	0.00319	CcSEcCtD
Bisoprolol—Body temperature increased—Sorafenib—liver cancer	0.00246	0.00318	CcSEcCtD
Bisoprolol—Abdominal pain—Sorafenib—liver cancer	0.00246	0.00318	CcSEcCtD
Bisoprolol—Purpura—Epirubicin—liver cancer	0.00243	0.00314	CcSEcCtD
Bisoprolol—Vascular purpura—Doxorubicin—liver cancer	0.00242	0.00313	CcSEcCtD
Bisoprolol—Eczema—Doxorubicin—liver cancer	0.00241	0.00312	CcSEcCtD
Bisoprolol—Eye pain—Doxorubicin—liver cancer	0.0024	0.0031	CcSEcCtD
Bisoprolol—Cardiac failure—Epirubicin—liver cancer	0.0024	0.0031	CcSEcCtD
Bisoprolol—Hypoglycaemia—Epirubicin—liver cancer	0.0024	0.0031	CcSEcCtD
Bisoprolol—Cardiac failure congestive—Doxorubicin—liver cancer	0.00239	0.00309	CcSEcCtD
Bisoprolol—Osteoarthritis—Epirubicin—liver cancer	0.00234	0.00303	CcSEcCtD
Bisoprolol—Hot flush—Doxorubicin—liver cancer	0.00232	0.00299	CcSEcCtD
Bisoprolol—Affect lability—Epirubicin—liver cancer	0.00231	0.00298	CcSEcCtD
Bisoprolol—Dermatitis exfoliative—Doxorubicin—liver cancer	0.0023	0.00297	CcSEcCtD
Bisoprolol—Menopausal symptoms—Doxorubicin—liver cancer	0.0023	0.00297	CcSEcCtD
Bisoprolol—Hypersensitivity—Sorafenib—liver cancer	0.0023	0.00297	CcSEcCtD
Bisoprolol—Purpura—Doxorubicin—liver cancer	0.00225	0.00291	CcSEcCtD
Bisoprolol—Asthenia—Sorafenib—liver cancer	0.00224	0.00289	CcSEcCtD
Bisoprolol—Cardiac arrest—Epirubicin—liver cancer	0.00223	0.00288	CcSEcCtD
Bisoprolol—Hypoglycaemia—Doxorubicin—liver cancer	0.00222	0.00287	CcSEcCtD
Bisoprolol—Cardiac failure—Doxorubicin—liver cancer	0.00222	0.00287	CcSEcCtD
Bisoprolol—Mood swings—Epirubicin—liver cancer	0.00222	0.00287	CcSEcCtD
Bisoprolol—Pruritus—Sorafenib—liver cancer	0.0022	0.00285	CcSEcCtD
Bisoprolol—Osteoarthritis—Doxorubicin—liver cancer	0.00217	0.0028	CcSEcCtD
Bisoprolol—Orthostatic hypotension—Epirubicin—liver cancer	0.00214	0.00276	CcSEcCtD
Bisoprolol—Abdominal pain upper—Epirubicin—liver cancer	0.00214	0.00276	CcSEcCtD
Bisoprolol—Affect lability—Doxorubicin—liver cancer	0.00213	0.00276	CcSEcCtD
Bisoprolol—Diarrhoea—Sorafenib—liver cancer	0.00213	0.00275	CcSEcCtD
Bisoprolol—Breast disorder—Epirubicin—liver cancer	0.00212	0.00273	CcSEcCtD
Bisoprolol—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00211	0.00273	CcSEcCtD
Bisoprolol—Gastritis—Epirubicin—liver cancer	0.00207	0.00268	CcSEcCtD
Bisoprolol—Muscular weakness—Epirubicin—liver cancer	0.00207	0.00267	CcSEcCtD
Bisoprolol—Cardiac arrest—Doxorubicin—liver cancer	0.00206	0.00266	CcSEcCtD
Bisoprolol—Dizziness—Sorafenib—liver cancer	0.00206	0.00266	CcSEcCtD
Bisoprolol—Mood swings—Doxorubicin—liver cancer	0.00205	0.00265	CcSEcCtD
Bisoprolol—Asthma—Epirubicin—liver cancer	0.00203	0.00262	CcSEcCtD
Bisoprolol—Vomiting—Sorafenib—liver cancer	0.00198	0.00256	CcSEcCtD
Bisoprolol—Abdominal pain upper—Doxorubicin—liver cancer	0.00198	0.00256	CcSEcCtD
Bisoprolol—Orthostatic hypotension—Doxorubicin—liver cancer	0.00198	0.00256	CcSEcCtD
Bisoprolol—Rash—Sorafenib—liver cancer	0.00196	0.00254	CcSEcCtD
Bisoprolol—Dermatitis—Sorafenib—liver cancer	0.00196	0.00254	CcSEcCtD
Bisoprolol—Breast disorder—Doxorubicin—liver cancer	0.00196	0.00253	CcSEcCtD
Bisoprolol—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00195	0.00252	CcSEcCtD
Bisoprolol—Headache—Sorafenib—liver cancer	0.00195	0.00252	CcSEcCtD
Bisoprolol—Bronchitis—Epirubicin—liver cancer	0.00195	0.00252	CcSEcCtD
Bisoprolol—Gastritis—Doxorubicin—liver cancer	0.00192	0.00248	CcSEcCtD
Bisoprolol—Muscular weakness—Doxorubicin—liver cancer	0.00191	0.00247	CcSEcCtD
Bisoprolol—Asthma—Doxorubicin—liver cancer	0.00187	0.00242	CcSEcCtD
Bisoprolol—Nausea—Sorafenib—liver cancer	0.00185	0.00239	CcSEcCtD
Bisoprolol—Photosensitivity reaction—Epirubicin—liver cancer	0.00185	0.00239	CcSEcCtD
Bisoprolol—Weight increased—Epirubicin—liver cancer	0.00184	0.00238	CcSEcCtD
Bisoprolol—Pneumonia—Epirubicin—liver cancer	0.00182	0.00235	CcSEcCtD
Bisoprolol—Drowsiness—Epirubicin—liver cancer	0.00181	0.00233	CcSEcCtD
Bisoprolol—Bronchitis—Doxorubicin—liver cancer	0.0018	0.00233	CcSEcCtD
Bisoprolol—Urinary tract infection—Epirubicin—liver cancer	0.00176	0.00227	CcSEcCtD
Bisoprolol—Conjunctivitis—Epirubicin—liver cancer	0.00176	0.00227	CcSEcCtD
Bisoprolol—Sweating—Epirubicin—liver cancer	0.00173	0.00224	CcSEcCtD
Bisoprolol—Photosensitivity reaction—Doxorubicin—liver cancer	0.00171	0.00221	CcSEcCtD
Bisoprolol—Hepatobiliary disease—Epirubicin—liver cancer	0.00171	0.00221	CcSEcCtD
Bisoprolol—Weight increased—Doxorubicin—liver cancer	0.00171	0.0022	CcSEcCtD
Bisoprolol—Sinusitis—Epirubicin—liver cancer	0.00169	0.00219	CcSEcCtD
Bisoprolol—Agranulocytosis—Epirubicin—liver cancer	0.00169	0.00218	CcSEcCtD
Bisoprolol—Pneumonia—Doxorubicin—liver cancer	0.00168	0.00217	CcSEcCtD
Bisoprolol—Drowsiness—Doxorubicin—liver cancer	0.00167	0.00216	CcSEcCtD
Bisoprolol—Bradycardia—Epirubicin—liver cancer	0.00165	0.00213	CcSEcCtD
Bisoprolol—Rhinitis—Epirubicin—liver cancer	0.00163	0.0021	CcSEcCtD
Bisoprolol—Urinary tract infection—Doxorubicin—liver cancer	0.00162	0.0021	CcSEcCtD
Bisoprolol—Conjunctivitis—Doxorubicin—liver cancer	0.00162	0.0021	CcSEcCtD
Bisoprolol—Hepatitis—Epirubicin—liver cancer	0.00162	0.00209	CcSEcCtD
Bisoprolol—Hypoaesthesia—Epirubicin—liver cancer	0.00161	0.00208	CcSEcCtD
Bisoprolol—Pharyngitis—Epirubicin—liver cancer	0.00161	0.00208	CcSEcCtD
Bisoprolol—Sweating—Doxorubicin—liver cancer	0.0016	0.00207	CcSEcCtD
Bisoprolol—Oedema peripheral—Epirubicin—liver cancer	0.0016	0.00206	CcSEcCtD
Bisoprolol—Connective tissue disorder—Epirubicin—liver cancer	0.00159	0.00206	CcSEcCtD
Bisoprolol—Hepatobiliary disease—Doxorubicin—liver cancer	0.00158	0.00204	CcSEcCtD
Bisoprolol—Sinusitis—Doxorubicin—liver cancer	0.00157	0.00202	CcSEcCtD
Bisoprolol—Visual impairment—Epirubicin—liver cancer	0.00156	0.00202	CcSEcCtD
Bisoprolol—Agranulocytosis—Doxorubicin—liver cancer	0.00156	0.00201	CcSEcCtD
Bisoprolol—Bradycardia—Doxorubicin—liver cancer	0.00153	0.00197	CcSEcCtD
Bisoprolol—Eye disorder—Epirubicin—liver cancer	0.00151	0.00196	CcSEcCtD
Bisoprolol—Tinnitus—Epirubicin—liver cancer	0.00151	0.00195	CcSEcCtD
Bisoprolol—Flushing—Epirubicin—liver cancer	0.0015	0.00194	CcSEcCtD
Bisoprolol—Cardiac disorder—Epirubicin—liver cancer	0.0015	0.00194	CcSEcCtD
Bisoprolol—Rhinitis—Doxorubicin—liver cancer	0.0015	0.00194	CcSEcCtD
Bisoprolol—Hepatitis—Doxorubicin—liver cancer	0.0015	0.00194	CcSEcCtD
Bisoprolol—Hypoaesthesia—Doxorubicin—liver cancer	0.00149	0.00193	CcSEcCtD
Bisoprolol—Pharyngitis—Doxorubicin—liver cancer	0.00149	0.00192	CcSEcCtD
Bisoprolol—Oedema peripheral—Doxorubicin—liver cancer	0.00148	0.00191	CcSEcCtD
Bisoprolol—Connective tissue disorder—Doxorubicin—liver cancer	0.00147	0.0019	CcSEcCtD
Bisoprolol—Angiopathy—Epirubicin—liver cancer	0.00147	0.0019	CcSEcCtD
Bisoprolol—Mediastinal disorder—Epirubicin—liver cancer	0.00146	0.00189	CcSEcCtD
Bisoprolol—Arrhythmia—Epirubicin—liver cancer	0.00145	0.00187	CcSEcCtD
Bisoprolol—Visual impairment—Doxorubicin—liver cancer	0.00145	0.00187	CcSEcCtD
Bisoprolol—Alopecia—Epirubicin—liver cancer	0.00143	0.00185	CcSEcCtD
Bisoprolol—Mental disorder—Epirubicin—liver cancer	0.00142	0.00183	CcSEcCtD
Bisoprolol—Erythema—Epirubicin—liver cancer	0.00141	0.00182	CcSEcCtD
Bisoprolol—Eye disorder—Doxorubicin—liver cancer	0.0014	0.00181	CcSEcCtD
Bisoprolol—Tinnitus—Doxorubicin—liver cancer	0.0014	0.00181	CcSEcCtD
Bisoprolol—Flushing—Doxorubicin—liver cancer	0.00139	0.0018	CcSEcCtD
Bisoprolol—Cardiac disorder—Doxorubicin—liver cancer	0.00139	0.0018	CcSEcCtD
Bisoprolol—Dysgeusia—Epirubicin—liver cancer	0.00138	0.00178	CcSEcCtD
Bisoprolol—Back pain—Epirubicin—liver cancer	0.00136	0.00176	CcSEcCtD
Bisoprolol—Angiopathy—Doxorubicin—liver cancer	0.00136	0.00176	CcSEcCtD
Bisoprolol—Muscle spasms—Epirubicin—liver cancer	0.00136	0.00175	CcSEcCtD
Bisoprolol—Mediastinal disorder—Doxorubicin—liver cancer	0.00135	0.00175	CcSEcCtD
Bisoprolol—Arrhythmia—Doxorubicin—liver cancer	0.00134	0.00173	CcSEcCtD
Bisoprolol—Alopecia—Doxorubicin—liver cancer	0.00133	0.00171	CcSEcCtD
Bisoprolol—Mental disorder—Doxorubicin—liver cancer	0.00131	0.0017	CcSEcCtD
Bisoprolol—Ill-defined disorder—Epirubicin—liver cancer	0.00131	0.00169	CcSEcCtD
Bisoprolol—Erythema—Doxorubicin—liver cancer	0.00131	0.00169	CcSEcCtD
Bisoprolol—Agitation—Epirubicin—liver cancer	0.0013	0.00167	CcSEcCtD
Bisoprolol—Dysgeusia—Doxorubicin—liver cancer	0.00128	0.00165	CcSEcCtD
Bisoprolol—Malaise—Epirubicin—liver cancer	0.00127	0.00164	CcSEcCtD
Bisoprolol—Vertigo—Epirubicin—liver cancer	0.00127	0.00164	CcSEcCtD
Bisoprolol—Syncope—Epirubicin—liver cancer	0.00127	0.00163	CcSEcCtD
Bisoprolol—Back pain—Doxorubicin—liver cancer	0.00126	0.00163	CcSEcCtD
Bisoprolol—Muscle spasms—Doxorubicin—liver cancer	0.00126	0.00162	CcSEcCtD
Bisoprolol—Palpitations—Epirubicin—liver cancer	0.00125	0.00161	CcSEcCtD
Bisoprolol—Loss of consciousness—Epirubicin—liver cancer	0.00124	0.0016	CcSEcCtD
Bisoprolol—Cough—Epirubicin—liver cancer	0.00123	0.00159	CcSEcCtD
Bisoprolol—Ill-defined disorder—Doxorubicin—liver cancer	0.00121	0.00156	CcSEcCtD
Bisoprolol—Arthralgia—Epirubicin—liver cancer	0.0012	0.00155	CcSEcCtD
Bisoprolol—Myalgia—Epirubicin—liver cancer	0.0012	0.00155	CcSEcCtD
Bisoprolol—Chest pain—Epirubicin—liver cancer	0.0012	0.00155	CcSEcCtD
Bisoprolol—Agitation—Doxorubicin—liver cancer	0.0012	0.00155	CcSEcCtD
Bisoprolol—Anxiety—Epirubicin—liver cancer	0.0012	0.00155	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00119	0.00154	CcSEcCtD
Bisoprolol—Discomfort—Epirubicin—liver cancer	0.00119	0.00153	CcSEcCtD
Bisoprolol—Malaise—Doxorubicin—liver cancer	0.00118	0.00152	CcSEcCtD
Bisoprolol—Dry mouth—Epirubicin—liver cancer	0.00117	0.00152	CcSEcCtD
Bisoprolol—Vertigo—Doxorubicin—liver cancer	0.00117	0.00152	CcSEcCtD
Bisoprolol—Syncope—Doxorubicin—liver cancer	0.00117	0.00151	CcSEcCtD
Bisoprolol—Confusional state—Epirubicin—liver cancer	0.00116	0.0015	CcSEcCtD
Bisoprolol—Palpitations—Doxorubicin—liver cancer	0.00115	0.00149	CcSEcCtD
Bisoprolol—Oedema—Epirubicin—liver cancer	0.00115	0.00149	CcSEcCtD
Bisoprolol—Loss of consciousness—Doxorubicin—liver cancer	0.00115	0.00148	CcSEcCtD
Bisoprolol—Infection—Epirubicin—liver cancer	0.00114	0.00148	CcSEcCtD
Bisoprolol—Cough—Doxorubicin—liver cancer	0.00114	0.00147	CcSEcCtD
Bisoprolol—Shock—Epirubicin—liver cancer	0.00113	0.00146	CcSEcCtD
Bisoprolol—Nervous system disorder—Epirubicin—liver cancer	0.00113	0.00146	CcSEcCtD
Bisoprolol—Thrombocytopenia—Epirubicin—liver cancer	0.00113	0.00146	CcSEcCtD
Bisoprolol—Tachycardia—Epirubicin—liver cancer	0.00112	0.00145	CcSEcCtD
Bisoprolol—Skin disorder—Epirubicin—liver cancer	0.00112	0.00144	CcSEcCtD
Bisoprolol—Hyperhidrosis—Epirubicin—liver cancer	0.00111	0.00144	CcSEcCtD
Bisoprolol—Chest pain—Doxorubicin—liver cancer	0.00111	0.00144	CcSEcCtD
Bisoprolol—Myalgia—Doxorubicin—liver cancer	0.00111	0.00144	CcSEcCtD
Bisoprolol—Arthralgia—Doxorubicin—liver cancer	0.00111	0.00144	CcSEcCtD
Bisoprolol—Anxiety—Doxorubicin—liver cancer	0.00111	0.00143	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.0011	0.00143	CcSEcCtD
Bisoprolol—Discomfort—Doxorubicin—liver cancer	0.0011	0.00142	CcSEcCtD
Bisoprolol—Dry mouth—Doxorubicin—liver cancer	0.00109	0.0014	CcSEcCtD
Bisoprolol—Hypotension—Epirubicin—liver cancer	0.00108	0.00139	CcSEcCtD
Bisoprolol—Confusional state—Doxorubicin—liver cancer	0.00107	0.00139	CcSEcCtD
Bisoprolol—Oedema—Doxorubicin—liver cancer	0.00107	0.00138	CcSEcCtD
Bisoprolol—Infection—Doxorubicin—liver cancer	0.00106	0.00137	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00105	0.00136	CcSEcCtD
Bisoprolol—Shock—Doxorubicin—liver cancer	0.00105	0.00135	CcSEcCtD
Bisoprolol—Nervous system disorder—Doxorubicin—liver cancer	0.00105	0.00135	CcSEcCtD
Bisoprolol—Thrombocytopenia—Doxorubicin—liver cancer	0.00104	0.00135	CcSEcCtD
Bisoprolol—Insomnia—Epirubicin—liver cancer	0.00104	0.00135	CcSEcCtD
Bisoprolol—Tachycardia—Doxorubicin—liver cancer	0.00104	0.00134	CcSEcCtD
Bisoprolol—Skin disorder—Doxorubicin—liver cancer	0.00104	0.00134	CcSEcCtD
Bisoprolol—Paraesthesia—Epirubicin—liver cancer	0.00103	0.00134	CcSEcCtD
Bisoprolol—Hyperhidrosis—Doxorubicin—liver cancer	0.00103	0.00133	CcSEcCtD
Bisoprolol—Dyspnoea—Epirubicin—liver cancer	0.00103	0.00133	CcSEcCtD
Bisoprolol—Somnolence—Epirubicin—liver cancer	0.00102	0.00132	CcSEcCtD
Bisoprolol—Dyspepsia—Epirubicin—liver cancer	0.00101	0.00131	CcSEcCtD
Bisoprolol—Hypotension—Doxorubicin—liver cancer	0.000996	0.00129	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Epirubicin—liver cancer	0.000994	0.00128	CcSEcCtD
Bisoprolol—Fatigue—Epirubicin—liver cancer	0.000993	0.00128	CcSEcCtD
Bisoprolol—Pain—Epirubicin—liver cancer	0.000985	0.00127	CcSEcCtD
Bisoprolol—Constipation—Epirubicin—liver cancer	0.000985	0.00127	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000971	0.00125	CcSEcCtD
Bisoprolol—Insomnia—Doxorubicin—liver cancer	0.000964	0.00124	CcSEcCtD
Bisoprolol—Paraesthesia—Doxorubicin—liver cancer	0.000957	0.00124	CcSEcCtD
Bisoprolol—Dyspnoea—Doxorubicin—liver cancer	0.00095	0.00123	CcSEcCtD
Bisoprolol—Feeling abnormal—Epirubicin—liver cancer	0.000949	0.00123	CcSEcCtD
Bisoprolol—Somnolence—Doxorubicin—liver cancer	0.000947	0.00122	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Epirubicin—liver cancer	0.000942	0.00122	CcSEcCtD
Bisoprolol—Dyspepsia—Doxorubicin—liver cancer	0.000938	0.00121	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00092	0.00119	CcSEcCtD
Bisoprolol—Fatigue—Doxorubicin—liver cancer	0.000919	0.00119	CcSEcCtD
Bisoprolol—Urticaria—Epirubicin—liver cancer	0.000915	0.00118	CcSEcCtD
Bisoprolol—Pain—Doxorubicin—liver cancer	0.000911	0.00118	CcSEcCtD
Bisoprolol—Constipation—Doxorubicin—liver cancer	0.000911	0.00118	CcSEcCtD
Bisoprolol—Body temperature increased—Epirubicin—liver cancer	0.00091	0.00118	CcSEcCtD
Bisoprolol—Abdominal pain—Epirubicin—liver cancer	0.00091	0.00118	CcSEcCtD
Bisoprolol—Feeling abnormal—Doxorubicin—liver cancer	0.000878	0.00113	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Doxorubicin—liver cancer	0.000871	0.00113	CcSEcCtD
Bisoprolol—Hypersensitivity—Epirubicin—liver cancer	0.000849	0.0011	CcSEcCtD
Bisoprolol—Urticaria—Doxorubicin—liver cancer	0.000847	0.00109	CcSEcCtD
Bisoprolol—Abdominal pain—Doxorubicin—liver cancer	0.000842	0.00109	CcSEcCtD
Bisoprolol—Body temperature increased—Doxorubicin—liver cancer	0.000842	0.00109	CcSEcCtD
Bisoprolol—Asthenia—Epirubicin—liver cancer	0.000826	0.00107	CcSEcCtD
Bisoprolol—Pruritus—Epirubicin—liver cancer	0.000815	0.00105	CcSEcCtD
Bisoprolol—Diarrhoea—Epirubicin—liver cancer	0.000788	0.00102	CcSEcCtD
Bisoprolol—Hypersensitivity—Doxorubicin—liver cancer	0.000785	0.00101	CcSEcCtD
Bisoprolol—Asthenia—Doxorubicin—liver cancer	0.000765	0.000987	CcSEcCtD
Bisoprolol—Dizziness—Epirubicin—liver cancer	0.000762	0.000984	CcSEcCtD
Bisoprolol—Pruritus—Doxorubicin—liver cancer	0.000754	0.000974	CcSEcCtD
Bisoprolol—Vomiting—Epirubicin—liver cancer	0.000732	0.000946	CcSEcCtD
Bisoprolol—Diarrhoea—Doxorubicin—liver cancer	0.000729	0.000942	CcSEcCtD
Bisoprolol—Rash—Epirubicin—liver cancer	0.000726	0.000938	CcSEcCtD
Bisoprolol—Dermatitis—Epirubicin—liver cancer	0.000725	0.000937	CcSEcCtD
Bisoprolol—Headache—Epirubicin—liver cancer	0.000721	0.000932	CcSEcCtD
Bisoprolol—Dizziness—Doxorubicin—liver cancer	0.000705	0.00091	CcSEcCtD
Bisoprolol—Nausea—Epirubicin—liver cancer	0.000684	0.000884	CcSEcCtD
Bisoprolol—Vomiting—Doxorubicin—liver cancer	0.000678	0.000875	CcSEcCtD
Bisoprolol—Rash—Doxorubicin—liver cancer	0.000672	0.000868	CcSEcCtD
Bisoprolol—Dermatitis—Doxorubicin—liver cancer	0.000671	0.000867	CcSEcCtD
Bisoprolol—Headache—Doxorubicin—liver cancer	0.000668	0.000862	CcSEcCtD
Bisoprolol—Nausea—Doxorubicin—liver cancer	0.000633	0.000818	CcSEcCtD
Bisoprolol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	1.34e-05	0.00367	CbGpPWpGaD
Bisoprolol—CYP2D6—Metapathway biotransformation—GPX3—liver cancer	1.32e-05	0.00364	CbGpPWpGaD
Bisoprolol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	1.27e-05	0.00348	CbGpPWpGaD
Bisoprolol—CYP2D6—Biological oxidations—HPGDS—liver cancer	1.26e-05	0.00347	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—NR1H4—liver cancer	1.23e-05	0.00339	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—GSTA3—liver cancer	1.21e-05	0.00334	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	1.2e-05	0.00329	CbGpPWpGaD
Bisoprolol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	1.12e-05	0.00309	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—GSTA4—liver cancer	1.11e-05	0.00305	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CHN2—liver cancer	1.11e-05	0.00305	CbGpPWpGaD
Bisoprolol—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	1.11e-05	0.00304	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	1.09e-05	0.00301	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CHN2—liver cancer	1.09e-05	0.00298	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—GSTA2—liver cancer	1.08e-05	0.00297	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—GSTA1—liver cancer	1.04e-05	0.00287	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—NAT2—liver cancer	1.03e-05	0.00284	CbGpPWpGaD
Bisoprolol—CYP2D6—Biological oxidations—CYP2E1—liver cancer	1.03e-05	0.00283	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	1.02e-05	0.0028	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IFT88—liver cancer	1.01e-05	0.00279	CbGpPWpGaD
Bisoprolol—CYP2D6—Metapathway biotransformation—CYP2E1—liver cancer	1.01e-05	0.00279	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IFT88—liver cancer	9.93e-06	0.00273	CbGpPWpGaD
Bisoprolol—CYP2D6—Biological oxidations—GGT1—liver cancer	9.44e-06	0.0026	CbGpPWpGaD
Bisoprolol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	9.09e-06	0.0025	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	8.65e-06	0.00238	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—TRIO—liver cancer	8.59e-06	0.00236	CbGpPWpGaD
Bisoprolol—CYP2D6—Biological oxidations—GSTP1—liver cancer	8.48e-06	0.00233	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—TRIO—liver cancer	8.4e-06	0.00231	CbGpPWpGaD
Bisoprolol—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	8.37e-06	0.0023	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—HPGDS—liver cancer	8.25e-06	0.00227	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—CCR4—liver cancer	8.23e-06	0.00226	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—CCR4—liver cancer	8.05e-06	0.00222	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—TRIO—liver cancer	7.8e-06	0.00214	CbGpPWpGaD
Bisoprolol—CYP2D6—Biological oxidations—GSTM1—liver cancer	7.79e-06	0.00214	CbGpPWpGaD
Bisoprolol—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	7.69e-06	0.00211	CbGpPWpGaD
Bisoprolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	7.65e-06	0.0021	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—TRIO—liver cancer	7.63e-06	0.0021	CbGpPWpGaD
Bisoprolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	7.48e-06	0.00206	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CCR4—liver cancer	7.48e-06	0.00206	CbGpPWpGaD
Bisoprolol—CYP2D6—Biological oxidations—CYP1A1—liver cancer	7.39e-06	0.00203	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CCR4—liver cancer	7.31e-06	0.00201	CbGpPWpGaD
Bisoprolol—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	7.29e-06	0.002	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—CYP2E1—liver cancer	6.72e-06	0.00185	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	6.63e-06	0.00182	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SHC3—liver cancer	6.22e-06	0.00171	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—GGT1—liver cancer	6.17e-06	0.0017	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SHC3—liver cancer	6.08e-06	0.00167	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR ligand binding—F2—liver cancer	5.82e-06	0.0016	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR ligand binding—F2—liver cancer	5.7e-06	0.00157	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—GSTP1—liver cancer	5.55e-06	0.00153	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—UGDH—liver cancer	5.53e-06	0.00152	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	5.47e-06	0.0015	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—EPT1—liver cancer	5.2e-06	0.00143	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—GSTM1—liver cancer	5.1e-06	0.0014	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	5.03e-06	0.00138	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—TAT—liver cancer	4.93e-06	0.00135	CbGpPWpGaD
Bisoprolol—CYP3A4—Biological oxidations—CYP1A1—liver cancer	4.83e-06	0.00133	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FST—liver cancer	4.83e-06	0.00133	CbGpPWpGaD
Bisoprolol—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	4.76e-06	0.00131	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PRKCE—liver cancer	4.74e-06	0.0013	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FST—liver cancer	4.72e-06	0.0013	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PRKCE—liver cancer	4.64e-06	0.00128	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TRIO—liver cancer	4.61e-06	0.00127	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TRIO—liver cancer	4.51e-06	0.00124	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCR4—liver cancer	4.42e-06	0.00121	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCR4—liver cancer	4.32e-06	0.00119	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PRKCE—liver cancer	4.3e-06	0.00118	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PRKCE—liver cancer	4.21e-06	0.00116	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—CSF2—liver cancer	4.19e-06	0.00115	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—CSF2—liver cancer	4.1e-06	0.00113	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CSF2—liver cancer	3.81e-06	0.00105	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CSF2—liver cancer	3.73e-06	0.00102	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—UGDH—liver cancer	3.61e-06	0.000994	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ADAM17—liver cancer	3.49e-06	0.00096	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ADAM17—liver cancer	3.42e-06	0.000939	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—EPT1—liver cancer	3.4e-06	0.000934	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CPT1B—liver cancer	3.35e-06	0.000921	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GLUL—liver cancer	3.35e-06	0.000921	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—F2—liver cancer	3.29e-06	0.000905	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PSMA4—liver cancer	3.28e-06	0.000903	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PSMD10—liver cancer	3.28e-06	0.000903	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NR1H4—liver cancer	3.23e-06	0.000888	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TAT—liver cancer	3.22e-06	0.000886	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—F2—liver cancer	3.22e-06	0.000885	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PSMD10—liver cancer	3.21e-06	0.000883	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PSMA4—liver cancer	3.21e-06	0.000883	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTA3—liver cancer	3.17e-06	0.000873	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CG—liver cancer	3.15e-06	0.000866	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CG—liver cancer	3.08e-06	0.000847	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—F2—liver cancer	2.99e-06	0.000822	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—F2—liver cancer	2.92e-06	0.000804	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTA4—liver cancer	2.9e-06	0.000798	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CG—liver cancer	2.86e-06	0.000787	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTA2—liver cancer	2.83e-06	0.000778	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CG—liver cancer	2.8e-06	0.000769	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CD—liver cancer	2.77e-06	0.000761	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTA1—liver cancer	2.73e-06	0.000751	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CD—liver cancer	2.71e-06	0.000745	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NAT2—liver cancer	2.7e-06	0.000742	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ALDOB—liver cancer	2.59e-06	0.000712	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PRKCE—liver cancer	2.54e-06	0.000699	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CD—liver cancer	2.51e-06	0.000691	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PRKCE—liver cancer	2.49e-06	0.000684	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CRABP1—liver cancer	2.47e-06	0.000679	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CD—liver cancer	2.46e-06	0.000676	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CB—liver cancer	2.41e-06	0.000664	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IGF2—liver cancer	2.41e-06	0.000663	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CB—liver cancer	2.36e-06	0.000649	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IGF2—liver cancer	2.36e-06	0.000648	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CSF2—liver cancer	2.25e-06	0.000619	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—RAF1—liver cancer	2.24e-06	0.000617	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—H2AFX—liver cancer	2.22e-06	0.00061	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—IL2—liver cancer	2.22e-06	0.00061	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CSF2—liver cancer	2.2e-06	0.000605	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—RAF1—liver cancer	2.2e-06	0.000604	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CB—liver cancer	2.19e-06	0.000603	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GLUL—liver cancer	2.19e-06	0.000602	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CPT1B—liver cancer	2.19e-06	0.000602	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—H2AFX—liver cancer	2.17e-06	0.000597	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—IL2—liver cancer	2.17e-06	0.000596	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HPGDS—liver cancer	2.16e-06	0.000593	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CB—liver cancer	2.14e-06	0.00059	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NR1H4—liver cancer	2.11e-06	0.000581	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA3—liver cancer	2.08e-06	0.000571	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL2—liver cancer	2.01e-06	0.000554	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TERT—liver cancer	2.01e-06	0.000551	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL2—liver cancer	1.97e-06	0.000541	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TERT—liver cancer	1.96e-06	0.000539	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PSMA4—liver cancer	1.92e-06	0.000529	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PSMD10—liver cancer	1.92e-06	0.000529	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA4—liver cancer	1.9e-06	0.000522	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GOT2—liver cancer	1.87e-06	0.000515	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA2—liver cancer	1.85e-06	0.000509	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KDR—liver cancer	1.83e-06	0.000504	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAPK14—liver cancer	1.82e-06	0.000501	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KDR—liver cancer	1.79e-06	0.000493	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ESR1—liver cancer	1.79e-06	0.000492	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA1—liver cancer	1.78e-06	0.000491	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAPK14—liver cancer	1.78e-06	0.00049	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—F2—liver cancer	1.77e-06	0.000486	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NAT2—liver cancer	1.76e-06	0.000485	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP2E1—liver cancer	1.76e-06	0.000484	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ESR1—liver cancer	1.75e-06	0.000481	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—F2—liver cancer	1.73e-06	0.000475	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ALDOB—liver cancer	1.69e-06	0.000465	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—APC—liver cancer	1.69e-06	0.000465	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CG—liver cancer	1.69e-06	0.000465	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—APC—liver cancer	1.65e-06	0.000455	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CG—liver cancer	1.65e-06	0.000455	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYCS—liver cancer	1.65e-06	0.000453	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GGT1—liver cancer	1.61e-06	0.000444	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GOT1—liver cancer	1.61e-06	0.000444	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CRABP1—liver cancer	1.61e-06	0.000444	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—BRAF—liver cancer	1.59e-06	0.000437	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—BRAF—liver cancer	1.55e-06	0.000427	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CD—liver cancer	1.49e-06	0.000408	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CA—liver cancer	1.47e-06	0.000405	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SERPINE1—liver cancer	1.47e-06	0.000404	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—KRAS—liver cancer	1.45e-06	0.0004	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CD—liver cancer	1.45e-06	0.0004	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTP1—liver cancer	1.45e-06	0.000399	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CA—liver cancer	1.44e-06	0.000396	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SERPINE1—liver cancer	1.44e-06	0.000395	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HMOX1—liver cancer	1.43e-06	0.000393	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—KRAS—liver cancer	1.42e-06	0.000391	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HPGDS—liver cancer	1.41e-06	0.000388	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CA—liver cancer	1.34e-06	0.000367	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTM1—liver cancer	1.33e-06	0.000367	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—RAF1—liver cancer	1.33e-06	0.000365	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CA—liver cancer	1.31e-06	0.000359	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—RAF1—liver cancer	1.3e-06	0.000357	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MTOR—liver cancer	1.29e-06	0.000356	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CB—liver cancer	1.29e-06	0.000356	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MTOR—liver cancer	1.27e-06	0.000348	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CB—liver cancer	1.27e-06	0.000348	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP1A1—liver cancer	1.26e-06	0.000348	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PSMA4—liver cancer	1.26e-06	0.000346	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PSMD10—liver cancer	1.26e-06	0.000346	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—HRAS—liver cancer	1.24e-06	0.00034	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GOT2—liver cancer	1.22e-06	0.000336	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1B—liver cancer	1.21e-06	0.000334	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—HRAS—liver cancer	1.21e-06	0.000333	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—AKT1—liver cancer	1.2e-06	0.000331	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CASP3—liver cancer	1.19e-06	0.000327	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL2—liver cancer	1.19e-06	0.000327	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1B—liver cancer	1.19e-06	0.000327	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL6—liver cancer	1.18e-06	0.000325	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—MTHFR—liver cancer	1.18e-06	0.000324	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—AKT1—liver cancer	1.18e-06	0.000323	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CASP3—liver cancer	1.16e-06	0.00032	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL2—liver cancer	1.16e-06	0.00032	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCND1—liver cancer	1.16e-06	0.000319	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL6—liver cancer	1.16e-06	0.000318	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JUN—liver cancer	1.16e-06	0.000318	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PPARA—liver cancer	1.16e-06	0.000318	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP2E1—liver cancer	1.15e-06	0.000316	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CTNNB1—liver cancer	1.15e-06	0.000316	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCND1—liver cancer	1.13e-06	0.000312	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JUN—liver cancer	1.13e-06	0.000311	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MMP9—liver cancer	1.13e-06	0.000309	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CTNNB1—liver cancer	1.12e-06	0.000309	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1A—liver cancer	1.12e-06	0.000308	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MMP9—liver cancer	1.1e-06	0.000303	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1A—liver cancer	1.1e-06	0.000302	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAPK8—liver cancer	1.09e-06	0.000301	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—AKT1—liver cancer	1.09e-06	0.0003	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYCS—liver cancer	1.08e-06	0.000296	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAPK8—liver cancer	1.07e-06	0.000294	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—AKT1—liver cancer	1.07e-06	0.000294	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GOT1—liver cancer	1.06e-06	0.00029	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GGT1—liver cancer	1.06e-06	0.00029	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—VEGFA—liver cancer	1.01e-06	0.000278	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—STAT3—liver cancer	1e-06	0.000275	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CG—liver cancer	9.9e-07	0.000272	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—VEGFA—liver cancer	9.88e-07	0.000272	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STAT3—liver cancer	9.79e-07	0.000269	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PPARG—liver cancer	9.55e-07	0.000263	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTP1—liver cancer	9.48e-07	0.000261	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HMOX1—liver cancer	9.35e-07	0.000257	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MYC—liver cancer	9.3e-07	0.000256	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TGFB1—liver cancer	9.27e-07	0.000255	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MYC—liver cancer	9.09e-07	0.00025	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TGFB1—liver cancer	9.07e-07	0.000249	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTM1—liver cancer	8.71e-07	0.00024	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CD—liver cancer	8.7e-07	0.000239	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KRAS—liver cancer	8.59e-07	0.000236	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ALB—liver cancer	8.59e-07	0.000236	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KRAS—liver cancer	8.4e-07	0.000231	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP1A1—liver cancer	8.26e-07	0.000227	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CA—liver cancer	7.89e-07	0.000217	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CA—liver cancer	7.72e-07	0.000212	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MTHFR—liver cancer	7.7e-07	0.000212	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TP53—liver cancer	7.63e-07	0.00021	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CB—liver cancer	7.58e-07	0.000209	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PPARA—liver cancer	7.56e-07	0.000208	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TP53—liver cancer	7.47e-07	0.000205	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HRAS—liver cancer	7.3e-07	0.000201	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HRAS—liver cancer	7.14e-07	0.000196	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL6—liver cancer	6.99e-07	0.000192	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL6—liver cancer	6.84e-07	0.000188	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CG—liver cancer	6.47e-07	0.000178	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—AKT1—liver cancer	6.45e-07	0.000177	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—AKT1—liver cancer	6.31e-07	0.000173	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PPARG—liver cancer	6.25e-07	0.000172	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CD—liver cancer	5.69e-07	0.000156	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ALB—liver cancer	5.62e-07	0.000154	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CB—liver cancer	4.96e-07	0.000136	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CA—liver cancer	4.62e-07	0.000127	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—AKT1—liver cancer	3.78e-07	0.000104	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CA—liver cancer	3.02e-07	8.31e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—AKT1—liver cancer	2.47e-07	6.79e-05	CbGpPWpGaD
